“These crabs have saved countless human lives,” said Will Harlan, a senior scientist at the Center for Biological Diversity. “Can we return the favor?” He points to the billions of horseshoe crabs harvested each year for their blood, which yields limulus amebocyte lysate (LAL) – a test that detects harmful bacteria in medical products, including COVID‑19 vaccines.
How the Biomedical Industry Uses Horseshoe Crabs
Across the United States, hundreds of thousands of horseshoe crabs are captured annually for LAL testing. Massachusetts hosts two of the nation’s largest bleeding facilities, operated by Charles River Laboratories and Associates of Cape Cod, which both extract blood and produce synthetic reagents as alternatives to crab‑derived tests.
Some drugmakers are moving away from the crab‑based assay, but the high upfront costs and regulatory hurdles of switching products already approved with “blue blood” have slowed adoption.
The Massachusetts Division of Marine Fisheries says it is not the agency’s role to evaluate the effectiveness of synthetic alternatives.
Proposed Changes to Crab Harvest Quotas
The Division of Marine Fisheries proposed in late January to raise the biomedical harvest limit from 200,000 to 280,000 crabs, while reducing the bait quota from 140,000 to 100,000. Public comments will be accepted before final recommendations are presented in March.
Marine biologist Daniel McKiernan explained that the shift reflects growing demand from the biomedical sector and a decline in bait‑related demand. He noted that because a fraction of crabs die during bleeding, the reallocation could actually lower the total number of crabs killed each year.
Conservationists argue the proposal is “mathematical sleight‑of‑hand,” pointing out that the state is increasing biomedical catches at a time when companies should be reducing reliance on wild‑caught blood.
Industry and Community Reactions
Charles River Laboratories said it is reviewing the proposal and will participate in the public comment process, emphasizing work on “horseshoe crab conservation and supply chain sustainability.” Associates of Cape Cod declined to comment.
Local fishermen expressed concern that fewer biomedical permits could hurt income. Edward Barrett, a Marshfield fisherman, said many young anglers “need every dollar they can get,” and rely increasingly on crab harvests for their livelihood.
Shift Toward Synthetic Alternatives
In May, the US Pharmacopeia recognized lab‑made tests as a safe alternative to crab‑derived LAL. In November, Congress directed the FDA to modernize guidance, treating synthetic reagents as equivalent.
More drug companies are beginning the transition, though changing approvals for existing products remains challenging. Eli Lilly has already moved 80 % of its safety testing to synthetic reagents, a shift driven by senior director Jay Bolden, who highlighted ethical, ecological and supply‑chain benefits.
Bolden noted that “if you invest a little bit upfront, you will achieve those benefits — quality, supply chain, ethics, cost,” echoing Eli Lilly’s 2016 commitment to use synthetic reagents for all new products.
Frequently Asked Questions
What is limulus amebocyte lysate (LAL) and why is it important?
LAL is a substance derived from horseshoe crab blood that reacts to harmful bacteria. It has been used for decades to test the safety of implanted medical devices and injected medicines, including COVID‑19 vaccines.
What changes is Massachusetts proposing for horseshoe crab harvesting?
The state plans to raise the annual biomedical harvest quota from 200,000 to 280,000 crabs while cutting the bait quota from 140,000 to 100,000. The proposal is open for public comment before final recommendations are made in March.
Are synthetic alternatives to crab‑derived testing becoming widely accepted?
Yes. The US Pharmacopeia recognized lab‑made tests as safe in May, and Congress directed the FDA in November to treat synthetic reagents as equivalent. Several drug companies, including Eli Lilly, are shifting a large share of their safety testing to these alternatives.
How do you think the balance between medical safety and ecological preservation should be struck?